Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Overview of the complications of acute myeloid leukemia

INTRODUCTION

The clinical course of acute myeloid leukemia (AML) is complex, and the care of patients with AML should be entrusted to clinicians with sufficient knowledge and experience. Symptoms associated with anemia, infection, and bleeding occur almost universally as a consequence of the treatment and the disease itself. Other complications, such as leukostasis, metabolic abnormalities, and involvement of the central nervous system (CNS) may also be life-threatening, and must be rapidly diagnosed and treated, lest they interfere with appropriate treatment of the leukemia, either before chemotherapy can be given, or during the recovery period.

This topic will provide an overview of the complications of AML. The clinical features, diagnosis, classification, treatment, and overall prognosis of AML are discussed separately. (See "Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia" and "Induction therapy for acute myeloid leukemia in younger adults" and "Treatment of acute myeloid leukemia in older adults".)

ANEMIA

Patients with AML typically present with a normocytic, normochromic anemia that can vary in severity. This anemia worsens with induction chemotherapy and is managed primarily with blood transfusions. There is no role for the use of erythropoietic stimulating agents during induction therapy of AML. (See "Hematologic consequences of malignancy: Anemia and bleeding".)

The threshold for transfusion of packed red blood cells varies with patient age, symptoms, and the presence of medical comorbidities. In general, most centers recommend transfusion to asymptomatic patients with a hemoglobin ≤8 g/dL (5 mmol/liter). Blood products should be leukocyte depleted to reduce the risk of alloimmunization and transmission of cytomegalovirus (CMV) [1,2]. Although graft versus host disease is very unusual in patients with leukemia receiving conventional chemotherapy, many centers routinely irradiate blood products for such patients. (See "Induction therapy for acute myeloid leukemia in younger adults", section on 'Transfusions'.)

Of importance, red cell transfusions may increase the whole blood viscosity of patients with hyperleukocytosis resulting in symptoms of leukostasis. As such, red blood cell transfusions should be administered very slowly, or, if possible, withheld until the blast count is reduced in such patients. (See "Hyperleukocytosis and leukostasis", section on 'Supportive care'.)

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Jun 25, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337:1861.
  2. Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78:246.
  3. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.
  4. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27:322.
  5. Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 1981; 60:218.
  6. Chumbley LC. Pseudohyperkalemia in acute myelocytic leukemia. JAMA 1970; 211:1007.
  7. Wiernik PH, Serpick AA. Clinical significance of serum and urinary muramidase activity in leukemia and other hematologic malignancies. Am J Med 1969; 46:330.
  8. Sillos EM, Shenep JL, Burghen GA, et al. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer 2001; 92:2237.
  9. Spinazzé S, Schrijvers D. Metabolic emergencies. Crit Rev Oncol Hematol 2006; 58:79.
  10. Rosenthal AR. Ocular manifestations of leukemia. A review. Ophthalmology 1983; 90:899.
  11. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39:1.
  12. Sharma T, Grewal J, Gupta S, Murray PI. Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role. Eye (Lond) 2004; 18:663.
  13. Karesh JW, Goldman EJ, Reck K, et al. A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings. J Clin Oncol 1989; 7:1528.
  14. Schnoll-Sussman F, Kurtz RC. Gastrointestinal emergencies in the critically ill cancer patient. Semin Oncol 2000; 27:270.
  15. Luzar MJ, Sharma HM. Leukemia and arthritis: including reports on light, immunofluorescent, and electron microscopy of the synovium. J Rheumatol 1983; 10:132.
  16. Marsh WL Jr, Bylund DJ, Heath VC, Anderson MJ. Osteoarticular and pulmonary manifestations of acute leukemia. Case report and review of the literature. Cancer 1986; 57:385.
  17. Evans TI, Nercessian BM, Sanders KM. Leukemic arthritis. Semin Arthritis Rheum 1994; 24:48.
  18. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27:4848.
  19. Ku GH, White RH, Chew HK, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113:3911.
  20. Ziegler S, Sperr WR, Knöbl P, et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005; 115:59.
  21. Mohren M, Markmann I, Jentsch-Ullrich K, et al. Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer 2006; 94:200.
  22. De Stefano V, Sorà F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3:1985.
  23. Melillo L, Grandone E, Colaizzo D, et al. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 2007; 117:215.
  24. Al Ameri A, Koller C, Kantarjian H, et al. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2010; 116:93.
  25. Sampat K, Rossi A, Garcia-Gutierrez V, et al. Characteristics of pericardial effusions in patients with leukemia. Cancer 2010; 116:2366.